<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Marrow transplantation is effective treatment for a number of <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematological diseases</z:e> in patients under the age of 50 who have an HLA-identical sibling donor </plain></SENT>
<SENT sid="1" pm="."><plain>It is successful in the treatment of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> with 70-85% long-term survival </plain></SENT>
<SENT sid="2" pm="."><plain>It offers 10-30% apparent cures for patients with <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> who have relapsed at least once, and for those with <z:hpo ids='HP_0011010'>chronic</z:hpo> myelocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> in <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Although still somewhat controversial, it appears to be the treatment of choice for patients with <z:hpo ids='HP_0011009'>acute</z:hpo> nonlymphoblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo> in first chemotherapy induced remission, and for those with <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> in the <z:hpo ids='HP_0011010'>chronic</z:hpo> phase since approximately 50-60% of these patients experience long-term, disease-free survival </plain></SENT>
<SENT sid="4" pm="."><plain>Patients with <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> grafted in second or subsequent remission may expect a 30% "cure" of their disease </plain></SENT>
<SENT sid="5" pm="."><plain>Marrow grafting is the only effective treatment for many patients with inherited immunologic deficiencies and certain genetic <z:e sem="disease" ids="C0267971" disease_type="Disease or Syndrome" abbrv="">storage diseases</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Cures of congenital Fanconi's <z:hpo ids='HP_0001903'>anemia</z:hpo>, <z:e sem="disease" ids="C1260899" disease_type="Disease or Syndrome" abbrv="BDS">Blackfan-Diamond</z:e> <z:hpo ids='HP_0001903'>anemia</z:hpo>, <z:hpo ids='HP_0011002'>osteopetrosis</z:hpo>, <z:hpo ids='HP_0004818'>paroxysmal nocturnal hemoglobinuria</z:hpo> and <z:e sem="disease" ids="C0002875" disease_type="Disease or Syndrome" abbrv="">thalassemia major</z:e> have been achieved </plain></SENT>
<SENT sid="7" pm="."><plain>Marrow transplantation is being explored for the therapy of patients with <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e>, <z:e sem="disease" ids="C0026986,C0033027" disease_type="Neoplastic Process" abbrv="">preleukemia</z:e>, <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo>, hairy cell <z:hpo ids='HP_0001909'>leukemia</z:hpo>, <z:e sem="disease" ids="C0149925" disease_type="Neoplastic Process" abbrv="SCLC">small cell lung cancer</z:e>, <z:e sem="disease" ids="C0153594" disease_type="Neoplastic Process" abbrv="">testicular cancer</z:e>, <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e> and <z:hpo ids='HP_0003006'>neuroblastoma</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Marrow transplantation has been limited by the fact that many patients do not have HLA-identical siblings and very few have monozygotic twins </plain></SENT>
<SENT sid="9" pm="."><plain>More recently, marrow transplants from HLA-nonidentical family members and even from unrelated donors have been successfully explored.(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>